RxDoctor Payments Data

Matthew House, DO

Psychiatry · Fresno, CANPI 1134192842

Payments from drug & device makers

$933in general payments, 2019–2025

Across 98 payments — averaging $9.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$175
  • Takeda Pharmaceuticals U.S.A., Inc.$156
  • Johnson & Johnson$121
  • Otsuka America Pharmaceutical, Inc.$110
  • Lundbeck LLC$100
  • Sunovion Pharmaceuticals Inc.$76
  • plus $195 from 5 others

What the payments were for

  • Food & beverage$933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$933 in reported general payments places this provider in the 70th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$140,326
Medicare patients
103
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$201,216
RexultiBrexpiprazole19$27,760
AuvelityDextromethorphan Hbr/Bupropion11$12,009
LunestaEszopiclone12$11,099
LamictalLamotrigine11$7,677
Aripiprazole85$6,436
Olanzapine OdtOlanzapine18$5,641
Lisdexamfetamine Dimesylate12$3,198
Methylphenidate ErMethylphenidate Hcl28$2,230
Bupropion XlBupropion Hcl103$1,692
Quetiapine Fumarate95$1,585
Gabapentin103$1,571
Duloxetine Hcl120$1,521
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine53$1,332
Clonazepam155$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$23$201,21625 claims
Otsuka America Pharmaceutical, Inc.Rexulti$110$27,76019 claims
Axsome Therapeutics, Inc.Auvelity$48$12,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →